轮状病毒仍然是一个重大的公共卫生威胁,特别是在低收入国家,它是严重急性儿童胃肠炎的主要原因,每年造成超过128,500人死亡。尽管2006年推出Rotarix和RotaTeq疫苗标志着降低死亡率的里程碑,大约83,158例可预防的死亡持续存在,在疫苗的可及性和有效性方面显示出持续的挑战。为了解决这些问题,已经开发出针对多种轮状病毒基因型的新型皮下疫苗制剂.该疫苗由来自9种不同轮状病毒基因型和亚基因型的9种VP8*蛋白组成(P[4],P[6],P[8]LI,P[8]LIII,P[8]LIV,P[9],P[11],P[14],和P[25])在大肠杆菌中表达。两组小鼠用单一免疫原免疫,来自轮状病毒Wa株的VP8*(P[8]LI),或者使用非价配方。小鼠免疫研究的初步结果显示了有希望的结果,引发针对九种免疫原中的六种的抗体应答。值得注意的是,与仅针对该基因型特异性免疫的小鼠相比,在使用非价疫苗免疫的组中观察到针对VP8*P[8]LI的抗体滴度显著更高.总的来说,针对多种轮状病毒基因型的肠胃外疫苗的开发代表了减轻轮状病毒相关发病率和死亡率的全球负担的有希望的策略。为疾病预防和控制提供了新的途径。
Rotavirus remains a significant public health threat, especially in low-income countries, where it is the leading cause of severe acute childhood gastroenteritis, contributing to over 128,500 deaths annually. Although the introduction of the Rotarix and RotaTeq vaccines in 2006 marked a milestone in reducing mortality rates, approximately 83,158 preventable deaths persisted, showing ongoing challenges in vaccine accessibility and effectiveness. To address these issues, a novel subcutaneous vaccine formulation targeting multiple rotavirus genotypes has been developed. This vaccine consists of nine VP8* proteins from nine distinct rotavirus genotypes and sub-genotypes (P[4], P[6], P[8]LI, P[8]LIII, P[8]LIV, P[9], P[11], P[14], and P[25]) expressed in E. coli. Two groups of mice were immunized either with a single immunogen, the VP8* from the rotavirus Wa strain (P[8]LI), or with the nonavalent formulation. Preliminary results from mouse immunization studies showed promising outcomes, eliciting antibody responses against six of the nine immunogens. Notably, significantly higher antibody titers against VP8* P[8]LI were observed in the group immunized with the nonavalent vaccine compared to mice specifically immunized against this genotype alone. Overall, the development of parenteral vaccines targeting multiple rotavirus genotypes represents a promising strategy in mitigating the global burden of rotavirus-related morbidity and mortality, offering new avenues for disease prevention and control.